Glaukos Corporation stocks have been trading up by 33.0 percent after investors cheered strong clinical glaucoma treatment developments.

Live Update At 15:02:56 EDT: On Thursday, October 29, 2026 Glaukos Corporation stock [NYSE: GKOS] is trending up by 33.0%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

GKOS just put on the kind of show that wakes up every momentum trader on the scanner. After weeks grinding in the $160s–$170s, Glaukos ripped from a prior close of $181.43 on 2026/10/28 to finish 2026/10/29 at $241.30. That’s a one‑day surge of roughly 33%, backed by real numbers, not hype.

The catalyst was Q3: Glaukos posted about $211M in revenue versus roughly $168M expected, and adjusted EPS of $0.47 versus a loss near -$0.10. For a name that still shows negative margins on trailing metrics, this kind of upside prints a clear message — the model is scaling. High gross margin around 60.7% gives GKOS a lot of room to drop more revenue to the bottom line as fixed costs are absorbed.

More Breaking News

• TE Stock Climbs As Traders Target Volatile Rebound
• FTAI Aviation Jumps As United Deal And Bullish Ratings Fuel Momentum
• Life Time Group Holdings Falls 2% Ahead of Earnings
• Lumentum Holdings Jumps 17% on Marvell Purchase Talks

Balance sheet strength backs the move. Glaukos runs with low leverage, a current ratio near 5, and solid working capital, so there is no obvious liquidity overhang. The daily and intraday charts show controlled, stair‑step buying rather than a wild pump, with GKOS grinding from the low $220s out of the open toward the $240s into the close. For active traders, this is classic “earnings gap and go” price action with real institutional support behind it.

Why Traders Are Watching GKOS Momentum

GKOS is now a textbook example of how a med‑tech growth story can transition from promise to execution in a single earnings print. The stock had already been trending higher for weeks, walking up from the mid‑$160s to the high‑$170s before the report. Then Glaukos dropped its Q3 numbers and guidance, and traders finally got confirmation of what the bulls were betting on.

The company didn’t just beat. It crushed expectations. Q3 revenue at $211M versus about $168M and EPS at $0.47 versus a loss signaled that iDose TR and Epioxa are not niche products — they are becoming real revenue drivers. That kind of delta versus consensus often triggers aggressive chasing from funds that were underweight the name, which helps explain the reported 14% post‑earnings pop and the continued follow‑through up toward $240+.

Guidance poured fuel on the fire. Glaukos now sees 2026 net sales at $775M–$785M and 2027 revenue hitting $1.0B, both well ahead of current Wall Street models. When a high‑growth, high‑multiple name like GKOS says the Street is too low by more than $100M in a single year, traders listen. It gives chart‑focused traders a fundamental backbone for breakouts and offers longer‑term swing traders a roadmap for why dips may get bought.

Layer on top the late‑stage clinical wins. Phase 4 iDose TR data in cataract surgery patients hit all primary and key secondary endpoints with favorable safety. Three‑year Phase 3 extension data for Epioxa in keratoconus showed durable vision gains with no repeat procedures needed. And the RevOpsis deal pushes GKOS into tri‑specific retinal biologics with RO‑104 and up to four more programs via the RevMod platform. Together, these moves tell traders Glaukos is not a one‑product story; it’s building a multi‑franchise ophthalmology platform with glaucoma, cornea, and retina all contributing to that $1.0B revenue target.

Conclusion

For active traders, GKOS now sits in that sweet spot where fundamentals, news flow, and price action all line up. Glaukos just delivered a huge Q3 beat, raised the bar for 2026 and 2027 revenue, and backed it up with strong late‑stage data in both iDose TR and Epioxa. The RevOpsis tie‑up adds another growth leg in retinal biologics, enlarging the long‑term story beyond its current glaucoma and corneal engines.

On the chart, Glaukos has shifted from a steady uptrend in the $160s–$170s to a high‑volume breakout in the $200s and now the $240 area. Intraday tape on 2026/10/29 showed consistent bids stepping up from the $210s at the open to the $240s into the close, not the kind of spiky action you usually see in crowded faders. That tells traders real demand was soaking up profit‑taking all day.

There are still risks — Mizuho has flagged possible procedure headwinds tied to Affordable Care Act and Medicaid changes, and GKOS remains a premium‑valued growth name. That’s where disciplined trading comes in. As Tim Sykes loves to remind traders, “Trade like a sniper, not a machine gun — wait for the best setups, then strike and cut losses fast.” Just as importantly, the learning process never stops; as Tim Bohen, lead trainer with StocksToTrade says, “The best way to learn is by tracking trades, wins, losses, and lessons learned. Every trade has something to teach.” For now, GKOS is on that best‑setups watchlist, and traders will be tracking every pullback, consolidation, and new data drop for the next high‑probability entry.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

• How to Read Stock Charts: A Guide for Beginners
• Trading Plan: 6 Steps to Create One
• How To Create a Stock Watchlist

Ready to build your watchlists? Check out these curated lists:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.